Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia

Haematologica

Volumn 96, Issue 11, 2011, Pages 1619-1626

  Kaufmann, Scott H ^a   Karp, Judith E ^b   Litzow, Mark R ^a   Mesa, Ruben A ^a   Hogan, William ^a   Steensma, David P ^a,c   Flatten, Karen S ^a   Loegering, David A ^a   Schneider, Paula A ^a   Peterson, Kevin L ^a   Maurer, Matthew J ^a   Smith, B Douglas ^b   Greer, Jacqueline ^b   Chen, Yuhong ^a   Reid, Joel M ^a   Ivy, S Percy ^d   Ames, Matthew M ^a   Adjei, Alex A ^a,e   Erlichman, Charles ^a   Karnitz, Larry M ^a  

^a Mayo Clinic College of Medicine   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Acute leukemia; Cytarabine; Pharmacological study; Phase I study; Tanespimycin

Indexed keywords

17 AMINOGELDANAMYCIN; CHECKPOINT KINASE 1; CYTARABINE; DRUG METABOLITE; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; TANESPIMYCIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CANCER RESISTANCE; CLINICAL ARTICLE; CONTINUOUS INFUSION; DISSEMINATED INTRAVASCULAR CLOTTING; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EXPOSURE; DRUG FATALITY; DRUG FORMULATION; DRUG HALF LIFE; FEBRILE NEUTROPENIA; FEMALE; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MALE; MAXIMUM TOLERATED DOSE; MONONUCLEAR CELL; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; QT PROLONGATION;

ACUTE DISEASE; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZOQUINONES; CYTARABINE; FEMALE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; LEUKEMIA; MALE; MIDDLE AGED; PROTEIN KINASES; RECURRENCE; TIME FACTORS;

EID: 80355125870     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.049551     Document Type: Article

References (47)

1. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer. 2005;5(10):761-772.
2. Pratt WB, Morishima Y, Osawa Y. The Hsp90 chaperone machinery regulates signaling by modulating ligand binding clefts. J Biol Chem. 2008;283(34):22885-22889.
3. Mahalingam D, Swords R, Carew JS, Nawrocki ST, Bhalla K, Giles FJ. Targeting HSP90 for cancer therapy. Br J Cancer. 2009;100(10):1523-1529.
4. Al Shaer L, Walsby E, Gilkes A, Tonks A, Walsh V, Mills K, et al. Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling. Br J Haematol. 2008;141(4):483-493.
5. Flandrin P, Guyotat D, Duval A, Cornillon J, Tavernier E, Nadal N, et al. Significance of heat-shock protein (HSP) 90 expression in acute myeloid leukemia cells. Cell Stress Chaperones. 2008;13(3):357-364.
6. Reikvam H, Ersvaer E, Bruserud O. Heat shock protein 90 - a potential target in the treatment of human acute myelogenous leuemia. Curr Cancer Drug Targets. 2009; 9(6):761-776.
7. Napper JM, Sollars VE. 17-N-Allylamino- 17-demethoxygeldanamycin induces a diverse response in human acute myelogenous cells. Leuk Res. 2010;34(11):1493-1500.
8. Nimmanapalli R, O'Bryan E, Bhalla K. Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts. Cancer Res. 2001;61(5):1799-1804.
9. Blagosklonny MV, Fojo T, Bhalla KN, Kim JS, Trepel JB, Figg WD, et al. The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl- expressing leukemia cells to cytotoxic chemotherapy. Leukemia. 2001; 15(10):1537-1543.
10. Minami Y, Kiyoi H, Yamamoto Y, Yamamoto K, Ueda R, Saito H, et al. Selective apoptosis of tandemly duplicated FLT3-transformed leukema cell inhibitors. Leukemia. 2002;16(8):1535-1540.
11. Yao Q, Nishiuchi R, Li Q, Kumar AR, Hudson WA, Kersey JH. FLT3 expressing leukemias are selectively sensitive to inibitors of the molecular chaperone heat shock protein 90 through destabilization of signal transduction-associated kinases. Clin Cancer Res. 2003;9(12):4483-4493.
12. Fumo G, Akin C, Metcalfe DD, Neckers L. 17-allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells. Blood. 2004; 103(3):1078-1084.
13. Basso AD, Solit DB, Chiosis G, Giri B, Tsichlis P, Rosen N. Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. J Biol Chem. 2002;277(42):39858-39866.
14. Nimmanapalli R, O'Bryan E, Kuhn D, Yamaguchi H, Wang HG, Bhalla KN. Regulation of 17-AAG-induced apoptosis: role of Bcl-2, Bcl-XL, and Bax downstream of 17-AAG-mediated down-regulation of Akt, Raf-1, and Src kinases. Blood. 2003;102(1):269-275.
15. Arlander SJ, Felts SJ, Wagner JM, Stensgard B, Toft DO, Karnitz LM. Chaperoning checkpoint kinase 1 (Chk1), an Hsp90 client, with purified chaperones. J Biol Chem. 2006;281(5):2989-2998.
16. Tillotson B, Slocum K, Coco J, Whitebread N, Thomas B, West KA, et al. Hsp90 (heat shock protein 90) inhibitor occupancy is a direct determinant of client protein degradation and tumor growth arrest in vivo. J Biol Chem. 2010;285(51):39835-39843.
17. Tang YC, Williams BR, Siegel JJ, Amon A. Identification of aneuploidy-selective antiproliferation compounds. Cell. 2011; 144(4):499-512.
18. Lancet JE, Gojo I, Burton M, Quinn M, Tighe SM, Kersey K, et al. Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia. Leukemia. 2010;24(4):699-705.
19. Radujkovic A, Schad M, Topaly J, Veldwijk MR, Laufs S, Schultheis BS, et al. Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL--inhibition of P-glycoprotein function by 17-AAG. Leukemia. 2005;19(7):1198-1206.
20. George P, Bali P, Cohen P, Tao J, Guo F, Sigua C, et al. Cotreatment with 17-allylamino- demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3. Cancer Res. 2004;64(10):3645-3652.
21. Rahmani M, Reese E, Dai Y, Bauer C, Kramer LB, Huang M, et al. Cotreatment with suberanoylanilide hydroxamic acid and 17-allylamino 17-demethoxygeldanamycin synergistically induces apoptosis in Bcr-Abl+ cells sensitive and resistant to STI571 (imatinib mesylate) in association with down-regulation of Bcr-Abl, abrogation of signal transducer and activator of transcription 5 activity, and Bax conformational change. Mol Pharmacol. 2005;67(4):1166-1176.
22. Rao R, Fiskus W, Yang Y, Lee P, Joshi R, Fernandez P, et al. HDAC6 inhibition enhances 17-AAG--mediated abrogation of hsp90 chaperone function in human leukemia cells. Blood. 2008;112(5):1886-1893.
23. Yao Q, Weigel B, Kersey J. Synergism between etoposide and 17-AAG in leukemia cells: critical roles for Hsp90, FLT3, topoisomerase II, Chk1, and Rad51. Clin Cancer Res. 2007;13(5):1591-1600.
24. Mesa RA, Loegering D, Powell HL, Flatten K, Arlander SAH, Dai NT, et al. Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine. Blood. 2005;106(1):318-327.
25. Zhao H, Piwnica-Worms H. ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1. Mol Cell Biol. 2001;21(13):4129-4139.
26. Cho SH, Toouli CD, Fujii GH, Crain C, Parry D. Chk1 is essential for tumor cell viability following activation of the replication checkpoint. Cell Cycle. 2005;4(1):131-139.
27. O'Connell M J, Cimprich KA. G2 damage checkpoints: what is the turn-on? J Cell Sci. 2005;118(Pt 1):1-6.
28. Arlander SJH, Eapen AK, Vroman BT, McDonald RJ, Toft DO, Karnitz LM. Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress. J Biol Chem. 2003;278(52):52572-52577.
29. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia in the Cancer and Leukemia Group B. N Engl J Med. 1994;331(14):896-903.
30. Major PP, Egan EM, Beardsley GP, Minden MD, Kufe DW. Lethality of human myeloblasts correlates with the incorporation of arabinofuranosylcytosine into DNA. Proc Natl Acad Sci USA. 1981; 78(5):3235-3239.
31. Pelicano H, Carew JS, McQueen TJ, Andreeff M, Plunkett W, Keating MJ, et al. Targeting Hsp90 by 17-AAG in leukemia cells: mechanisms for synergistic and antagonistic drug combinations with arsenic trioxide and Ara-C. Leukemia. 2006;20(4):610-619.
32. Goetz MP, Toft DO, Reid JM, Ames MM, Stensgard B, Safgren S, et al. A phase I trial of 17-allylamino-17- demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol. 2005; 23(6):1078-1087.
33. Kaufmann SH, Karp JE, Letendre L, Kottke TJ, Safgren S, Greer J, et al. Phase I and pharmacological study of infusional topotecan and carboplatin in relapsed and refractory leukemia. Clin Cancer Res. 2005;11(18):6641-6649.
34. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, et al. Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21(24):4642-4649.
35. Kaufmann SH, Svingen PA, Gore SD, Armstrong DK, Cheng Y-C, Rowinsky EK. Altered formation of topotecan-stabilized topoisomerase I-DNA adducts in human leukemia cells. Blood. 1997;89(6):2098-2104.
36. Wahner Hendrickson D, Haluska P, Schneider PA, Loegering DA, Peterson KL, Attar RM, et al. Expression of insulin receptor isoform a and insulin-like growth factor-1 receptor in human acute myeloid leukemia: Effect of the dual receptor inhibitor BMS-536924 in vitro. Cancer Res. 2009;69(19):7635-7643.
37. Kern W, Aul C, Maschmeyer G, Schonrock-Nabulsi R, Ludwig WD, Bartholomaus A, et al. Superiority of high-dose over intermediate- dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison. Leukemia. 1998;12(7):1049-1055.
38. Kaneko YS, Watanabe N, Morisaki H, Akita H, Fujimoto A, Tominaga K, et al. Cellcycle-dependent and ATM-independent expression of human Chk1 kinase. Oncogene. 1999;18(25):3673-3681.
39. Banerji U, O'Donnell A, Scurr M, Pacey S, Stapleton S, Asad Y, et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol. 2005;23(18): 4152-4161.
40. Guo F, Rocha K, Bali P, Pranpat M, Fiskus W, Boyapalle S, et al. Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylaminodemethoxy geldanamycin. Cancer Res. 2005;65(22):10536-10544.
41. McCollum AK, TenEyck CJ, Stensgard B, Morlan BW, Ballman KV, Jenkins RB, et al. P-Glycoprotein-mediated resistance to Hsp90-directed therapy is eclipsed by the heat shock response. Cancer Res. 2008;68 (18):7419-7427.
42. van Montfort RL, Workman P. Structurebased design of molecular cancer therapeutics. Trends Biotechnol. 2009;27(5):315-328.
43. Zabludoff SD, Deng C, Grondine MR, Sheehy AM, Ashwell S, Caleb BL, et al. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol Cancer Ther. 2008;7(9):2955-2966.
44. Dai Y, Grant S. New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin Cancer Res. 2010;16(2):376-383.
45. Guzi TJ, Paruch K, Dwyer MP, Labroli M, Shanahan F, Davis N, et al. Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening. Mol Cancer Ther. 2011;10(4):591-602.
46. Cheng GZ, Park S, Shu S, He L, Kong W, Zhang W, et al. Advances of AKT pathway in human oncogenesis and as a target for anti-cancer drug discovery. Curr Cancer Drug Targets. 2008;8(1):2-6.
47. Hixon ML, Paccagnella L, Millham R, Perez-Olle R, Gualberto A. Development of inhibitors of the IGF-IR/PI3K/Akt/mTOR pathway. Rev Recent Clin Trials. 2010;5(3): 189-208.